Takeda Pharmaceutical Company Limited (NYSE:TAK) is set to announce second quarter earning results on Thursday 29th October 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, TAK to report 2Q20 income of $ 0.99 per share from revenue of $ 7.62 million.
For the full year, analysts anticipate top line of $ 32.14 million, while looking forward to income of $ 4.26 per share bottom line.
Previous Quarter Performance
Takeda Pharmaceutical Company Limited recorded income for the first quarter of $ 1.14 per share, from the revenue of $ 7,458.00 million.
Stock Performance
Shares of Takeda Pharmaceutical Company Limited traded low $ -0.45 or -2.72 percent on Wednesday, reaching $ 16.10 with volume of 1.66 million shares. Takeda Pharmaceutical Company Limited has traded high as $ 16.38 and has cracked $ 16.09 on the downward trend
According to the previous trading day, closing price of $ 16.10, representing a 33.15 % increase from the 52 week low of $ 12.43 and a 20.93 % decrease over the 52 week high of $ 20.93.
The company has a market capital of $ 50.61 billion and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa.
